• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Marker Therapeutics, Inc.

    3/26/21 10:38:04 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRKR alert in real time by email
    SC 13D/A 1 nea16-marker_18483.htm NEW ENTERPRISE ASSOCIATES 16, L.P. (MARKER THERAPEUTICS) - SCHEDULE 13DA1 Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Marker Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value

    (Title of Class of Securities)

    57055L107

    (CUSIP Number)

    Louis S. Citron, Esq.

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600, Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    March 16, 2021

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 57055L107

    13D Page 2 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    New Enterprise Associates 16, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    WC

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Partnership

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    14,464,285 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    14,464,285 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,464,285 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    17.4%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

    CUSIP No. 57055L107

    13D Page 3 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    NEA Partners 16, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Partnership

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    14,464,285 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    14,464,285 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,464,285 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    17.4%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

      

     

     

     

     CUSIP No. 57055L107

    13D Page 4 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    NEA 16 GP, LLC

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Liability Company

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    14,464,285 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    14,464,285 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,464,285 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    17.4%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    OO

     

       

     

     

     

      

      CUSIP No. 57055L107

    13D Page 5 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Forest Baskett

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    14,464,285 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    14,464,285 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,464,285 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    17.4%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

     

    CUSIP No. 57055L107

    13D Page 6 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ali Behbahani

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    14,464,285 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    14,464,285 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,464,285 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    17.4%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 57055L107

    13D Page 7 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Carmen Chang

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    14,464,285 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    14,464,285 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,464,285 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    17.4%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

     

    CUSIP No. 57055L107

    13D Page 8 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Anthony A. Florence, Jr.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    14,464,285 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    14,464,285 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,464,285 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    17.4%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 57055L107

    13D Page 9 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Mohamad H. Makhzoumi

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    14,464,285 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

        14,464,285 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

        14,464,285 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    17.4%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 57055L107

    13D Page 10 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Joshua Makower

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    14,464,285 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

        14,464,285 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,464,285 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    17.4%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 57055L107

    13D Page 11 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Scott D. Sandell

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    14,464,285 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    14,464,285 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,464,285 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    17.4%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 57055L107

    13D Page 12 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter W. Sonsini

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    14,464,285 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    14,464,285 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,464,285 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    17.4%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 57055L107

    13D Page 13 of 22 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Paul Walker

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States citizen

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    14,464,285 shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    14,464,285 shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,464,285 shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    17.4%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

     

    CUSIP No. 57055L107

    13D Page 14 of 22 Pages    

     

    Item 1.  Security and Issuer.

    This Amendment No. 1 (“Amendment No. 1”) to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on October 25, 2018, relating to the common stock, $0.001 par value (the “Common Stock”), of Marker Therapeutics, Inc. (the “Issuer”) having its principal executive office at 3200 Southwest Freeway, Suite 2500, Houston, Texas 77027.

     

    Certain terms used but not defined in this Amendment No. 1 have the meanings assigned thereto in the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported on the Schedule 13D.

     

    Item 2.  Identity and Background.

     

    This statement is being filed by:

     

    (a) New Enterprise Associates 16, L.P. (“NEA 16”), NEA Partners 16, L.P. (“NEA Partners 16”), which is the sole general partner of NEA 16; and NEA 16 GP, LLC (“NEA 16 LLC” and, together with NEA Partners 16, the “Control Entities”), which is the sole general partner of NEA Partners 16; and

     

    (b) Forest Baskett (“Baskett”), Ali Behbahani (“Behbahani”), Carmen Chang (“Chang”), Anthony A. Florence, Jr. (“Florence”), Mohamad H. Makhzoumi (“Makhzoumi”), Joshua Makower (“Makower”), Scott D. Sandell (“Sandell”), Peter W. Sonsini (“Sonsini”) and Paul Walker (“Walker”) (together, the “Managers”) and Peter J. Barris (“Barris”), David M. Mott (“Mott”) and Ravi Viswanathan (“Viswanathan”). The Managers are the managers of NEA 16 LLC.

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of NEA 16, each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Behbahani is New Enterprise Associates, 5425 Wisconsin Avenue, Suite 800, Chevy Chase, MD 20815. The address of the principal business office of Baskett, Chang, Makhzoumi, Makower, Sonsini and Walker is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10001.

     

    The principal business of NEA 16 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 16 is to act as the sole general partner of NEA 16. The principal business of NEA 16 LLC is to act as the sole general partner of NEA Partners 16. The principal business of each of the Managers is to manage the Control Entities, NEA 16 and a number of affiliated partnerships with similar businesses.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    NEA 16 LLC is a limited liability company organized under the laws of the State of Delaware. NEA 16 and NEA Partners 16 are limited partnerships organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.

     

    Item 3.  Source and Amount of Funds or Other Consideration.

    On March 16, 2021, the Issuer completed the closing of an underwritten offering (the “Offering”) of 28,572,000 shares of Common Stock. At the closing of the Offering, NEA 16 purchased an aggregate of 5,714,285 shares of Common Stock at the Offering price of $1.75 per share for an aggregate purchase price of $9,999,998.75. In addition, prior to the Offering, NEA 16 purchased an aggregate of 5,000,000 shares of Common Stock and 3,750,000 warrants to purchase Common Stock, exercisable immediately, at an exercise price of $5.00 per share with a five-year term for an aggregate purchase price of $20,000,000 in a private placement transaction. NEA 16 now holds a total of 10,714,285 shares of Common Stock (the “NEA 16 Stock”) and 3,750,000 warrants to purchase Common Stock (the “NEA 16 Warrants” and, together with the NEA 16 Stock, the “NEA 16 Shares”).

     

    The working capital of NEA 16 was the source of the funds for the purchase of the NEA 16 Shares. No part of the purchase price of the NEA 16 Shares was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the NEA 16 Shares.

     

     

     

     

    CUSIP No. 57055L107

    13D Page 15 of 22 Pages    

     

     

     

    Item 4.  Purpose of Transaction.

     

    NEA 16 acquired the NEA 16 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 16 and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in:

     

    (a)The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

     

    (b)An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

     

    (c)A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

     

    (d)Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

     

    (e)Any material change in the present capitalization or dividend policy of the Issuer;

     

    (f)Any other material change in the Issuer’s business or corporate structure;

     

    (g)Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

     

    (h)Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

     

    (i)A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or

     

    (j)Any action similar to any of those enumerated above.

     

    Item 5.  Interest in Securities of the Issuer.

    (a)

    NEA 16 is the record owner of the NEA 16 Shares. As the general partner of NEA 16, NEA Partners 16 may be deemed to own beneficially the NEA 16 Shares. As the sole general partner of NEA Partners 16, NEA 16 LLC may be deemed to own beneficially the NEA 16 Shares. As members of NEA 16 LLC, each of the Managers may be deemed to own beneficially the NEA 16 Shares.

     

    Each Reporting Person disclaims beneficial ownership of the NEA 16 Shares other than those shares which such person owns of record.

     

    The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person’s cover sheet. Such percentage was calculated based on 83,053,072 shares of Common Stock which includes (i) 79,303,072 shares of Common Stock reported by the Issuer to be outstanding immediately after the Offering on the Issuer’s prospectus supplement filed under Rule 424(b)(5), filed with the Securities and Exchange Commission on March 15, 2021 and (ii) the NEA 16 Warrants.

     

     

     

    CUSIP No. 57055L107

    13D Page 16 of 22 Pages    

     

    (b)Regarding the number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: See line 7 of cover sheets

     

    (ii)shared power to vote or to direct the vote: See line 8 of cover sheets

     

    (iii)sole power to dispose or to direct the disposition: See line 9 of cover sheets

     

    (iv)shared power to dispose or to direct the disposition: See line 10 of cover sheets

     

    (c)Except as set forth in Item 3 above, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days.

     

    (d)No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Common Stock beneficially owned by any of the Reporting Persons.

     

    (e)

    Each of Barris, Mott and Viswanathan has ceased to own beneficially five percent or more of the Issuer’s Common Stock.

     

    Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Not applicable.

     

    Item 7.  Material to Be Filed as Exhibits.

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 57055L107

    13D Page 17 of 22 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 26th day of March, 2021.

     

     

    NEW ENTERPRISE ASSOCIATES 16, L.P.

     

    By:

    NEA PARTNERS 16, L.P.

    General Partner

     

    By:

    NEA 16 GP, LLC

    General Partner

      

      By:          *                                

     Scott D. Sandell

     Chief Executive Officer 

     

    NEA PARTNERS 16, L.P.

     

    By:NEA 16 GP, LLC
    General Partner

     

    By:          *                                

    Scott D. Sandell

    Chief Executive Officer

     

      

    NEA 16 GP, LLC

     

    By:          *                                

    Scott D. Sandell

    Chief Executive Officer

     

     

     

     

     

     

    CUSIP No. 57055L107

    13D Page 18 of 22 Pages    

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Ali Behbahani

     

     

                     *                        

    Carmen Chang

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Joshua Makower

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

                     *                        

    Paul Walker 

     

     

    */s/ Sasha O. Keough           

    Sasha O. Keough

    As attorney-in-fact

     

     

    This Amendment No. 1 to Schedule 13D was executed by Sasha O. Keough on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

     

     

     

     

     

     

     
     

     

    CUSIP No. 57055L107

    13D Page 19 of 22 Pages    

     

    EXHIBIT 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Marker Therapeutics, Inc.

     

    EXECUTED this 26th day of March, 2021.

     

     

    NEW ENTERPRISE ASSOCIATES 16, L.P.

     

    By:

    NEA PARTNERS 16, L.P.

    General Partner

     

    By:

    NEA 16 GP, LLC

    General Partner

      

      By:          *                                

     Scott D. Sandell

     Chief Executive Officer 

     

    NEA PARTNERS 16, L.P.

     

    By:NEA 16 GP, LLC
    General Partner

     

    By:          *                                

    Scott D. Sandell

    Chief Executive Officer

     

      

    NEA 16 GP, LLC

     

    By:          *                                

    Scott D. Sandell

    Chief Executive Officer

     

     

     

     

     

     

    CUSIP No. 57055L107

    13D Page 20 of 22 Pages    

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Ali Behbahani

     

     

                     *                        

    Carmen Chang

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Joshua Makower

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

                     *                        

    Paul Walker 

     

     

     

     

     

    */s/ Sasha O. Keough           

    Sasha O. Keough

    As attorney-in-fact

    This Agreement relating to Schedule 13D was executed by Sasha O. Keough on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached hereto as Exhibit 2.

     

     

     

     

     

    CUSIP No. 57055L107

    13D Page 21 of 22 Pages    

    EXHIBIT 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Louis S. Citron, Timothy Schaller, Sasha Keough and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 13th day of March, 2017.

     

     

    /s/ M. James Barrett            

    M. James Barrett

     

    /s/ Peter J. Barris                

    Peter J. Barris

     

    /s/ Forest Baskett                

    Forest Baskett

     

    /s/ Ali Behbahani                 

    Ali Behbahani

     

    /s/ Colin Bryant                   

    Colin Bryant

     

    /s/ Carmen Chang               

    Carmen Chang

     

    /s/ Anthony A. Florence, Jr.

    Anthony A. Florence, Jr.

     

    /s/ Carol G. Gallagher          

    Carol G. Gallagher

     

    /s/ Dayna Grayson               

    Dayna Grayson

     

    /s/ Patrick J. Kerins             

    Patrick J. Kerins

     

    /s/ P. Justin Klein                

    P. Justin Klein

     

     

     

     

     

    CUSIP No. 57055L107

    13D Page 22 of 22 Pages    

     

     

     

     

    /s/ Vanessa Larco               

    Vanessa Larco

     

    /s/ Joshua Makower             

    Joshua Makower

     

    /s/ Mohamad H. Makhzoumi

    Mohamad H. Makhzoumi

     

    /s/ Edward T. Mathers         

    Edward T. Mathers

     

    /s/ David M. Mott                

    David M. Mott

     

    /s/ Sara M. Nayeem            

    Sara M. Nayeem

     

    /s/ Jason R. Nunn                

    Jason R. Nunn

     

    /s/ Gregory Papadopoulos    

    Gregory Papadopoulos

     

    /s/ Chetan Puttagunta          

    Chetan Puttagunta

     

    /s/ Jon Sakoda                     

    Jon Sakoda

     

    /s/ Scott D. Sandell              

    Scott D. Sandell

     

    /s/ A. Brooke Seawell          

    A. Brooke Seawell

     

    /s/ Peter W. Sonsini             

    Peter W. Sonsini

     

    /s/ Melissa Taunton             

    Melissa Taunton

     

    /s/ Frank M. Torti                

    Frank M. Torti

     

    /s/ Ravi Viswanathan           

    Ravi Viswanathan

     

    /s/ Paul E. Walker               

    Paul E. Walker

     

    /s/ Rick Yang                      

    Rick Yang

     

     

     

     

     

     

     

    Get the next $MRKR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRKR

    DatePrice TargetRatingAnalyst
    3/5/2025$8.00Buy
    Canaccord Genuity
    2/17/2022$3.00 → $1.00Buy → Neutral
    Roth Capital
    More analyst ratings

    $MRKR
    Leadership Updates

    Live Leadership Updates

    See more
    • Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

      HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?". The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT. This one-hour virtual event will feature insights from leading voices in the cell therapy space, f

      5/19/25 8:00:12 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

      CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo

      8/28/24 8:00:00 AM ET
      $KRRO
      $MRKR
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

      Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR T relapse Secured non-dilutive funding of $2 million from National Institute of Health (NIH) to support clinical program for treatment of patients with Acute Myeloid Leukemia (AML) Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell product candidate MT-401 (Zedenoleucel) for the treatment of patients with AML Implemented leadership transition resulting in appointments of Juan Vera, M.D. as President and Chief Executive Officer and Monic St

      3/25/24 5:45:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

      HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?". The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT. This one-hour virtual event will feature insights from leading voices in the cell therapy space, f

      5/19/25 8:00:12 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

      HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity's Horizons in Oncology Virtual Conference. Dr. Vera will join company executives and key opinion leaders to discuss innovations in T cell-based immunotherapies as part of a panel focused on the future of CAR-T and other novel approaches in solid tumors. Panel Participation Details: EventCG Horizons in Onc

      4/1/25 8:00:14 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

      Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses Secured over $13 million in non-dilutive funding from the Cancer Prevention & Research Institute of Texas (CPRIT) and the National Institute of Health (NIH) Small Business Innovation Research (SBIR) to support pancreatic and lymphoma clinical programs Approval from United States Adopted Name (USAN) council and International Nonproprietary Names (INN) expert committee for "neldaleucel" as nonproprietary name for MT-601 Strategic financing to support cli

      3/31/25 8:45:00 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $MRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $MRKR
    SEC Filings

    See more
    • Director Elms Steve bought $35,472 worth of shares (11,085 units at $3.20) (SEC Form 4)

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      12/26/24 4:01:17 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner New Enterprise Associates 16, L.P. bought $1,773,600 worth of shares (554,250 units at $3.20) (SEC Form 4)

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      12/23/24 4:40:48 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Elms Steve

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:20:34 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Knobil Katharine

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:19:38 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Eansor Norman David

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:18:35 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Marker International with a new price target

      Canaccord Genuity initiated coverage of Marker International with a rating of Buy and set a new price target of $8.00

      3/5/25 7:37:58 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics downgraded by Roth Capital with a new price target

      Roth Capital downgraded Marker Therapeutics from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

      2/17/22 6:14:24 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Marker Therapeutics with a new price target

      Piper Sandler initiated coverage of Marker Therapeutics with a rating of Overweight and set a new price target of $6.00

      3/25/21 6:18:22 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Marker Therapeutics Inc. (Amendment)

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      5/17/24 6:25:14 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Marker Therapeutics, Inc.

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      3/26/21 10:38:04 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Marker Therapeutics, Inc.

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      3/15/21 4:45:13 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Marker Therapeutics, Inc. (0001094038) (Filer)

      6/9/25 4:13:33 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Marker Therapeutics, Inc. (0001094038) (Filer)

      5/20/25 8:32:01 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Marker Therapeutics Inc.

      10-Q - Marker Therapeutics, Inc. (0001094038) (Filer)

      5/15/25 5:00:50 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Financials

    Live finance-specific insights

    See more
    • Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

      Results from safety lead-in stage of Marker's Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading New T cell manufacturing process for MT-401 and other product candidates designed to improve potency, increase antigen specificity and diversity and significantly reduce manufacturing time Company announces clinical updates, including plans to file additional INDs by year end, with clinical trials in solid tumors and blood cancers to be initiated in 2023 Company to host conference call and webcast at 5:00 p.m. EST today HOUSTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, In

      2/16/22 4:30:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

      HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, February 16, 2022 at 5:00 p.m. EST to provide an update on the Company's clinical programs, manufacturing processes and pipeline. The webcast will be accessible in the Investors section of the Company's website at www.markertherapeutics.com. Individuals can participate in the conference call by dialing 877-869-3847 (domestic) or 201-68

      2/8/22 4:05:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

      HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.   "This quarter, we continued our momentum in advancing Marker's Phase 2 trial of MT-401, Marker's lead MultiTAA-specific T cell therapy, for the treatment of post-transplant acute myeloid leu

      11/10/21 4:05:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care